5-Year Cervical Cancer Screening Program Launched Vietnam

NZX/ASX Announcement

25 November 2024.
TruScreen launches 5- year Cervical Cancer Screening Program in Vietnam, with
Ho Chi Minh City Public Health Association (HPHA)

Highlights

• Tripartite Memorandum of Understanding (MOU) signed by TruScreen, Ho Chi
Minh City Public Health Association and distributor Gorton Health Services
(GHS)
• Program to c ommence in Q1 CY2025
• 5- year p rogram to screen 260,000 women in Ho Chi Minh City

TruScreen Group Limited (NZX/ASX:TRU) is pleased to announce that it has signed an
MOU with the Ho Chi Minh City Public Health Association and Gorton Health Services to
implement and conduct a public cervical cancer screening program in Ho Chi Minh City, which
has an estimated population of 13 million people.
TruScreen was selected by HPHA for its unique real time, non-invasive, objective cervical
cancer screening technology, requiring no pathology infrastructure, that suits the screening
program. The portability, ease of use and analytical algorithms real time results align with the
programs objective for early detection in large populations.
The program, titled “Community-based Proactive Cervical Cancer Screening Program” will
implement a proactive screening model where the program team contact women directly to
encourage them to attend screening, and to raise the awareness of the high mortality risk
from cervical cancer.
The program will screen patients in existing District Health Centres and Community Health
Clinics and may extend to mobile screening. The program will also support and monitor
patients with positive test results to attend follow up treatment, and to continue screening
throughout their lives.
HPHA was established in 2007 by the Peoples Committee of Ho Chi Minh City and is charged
with communication and education on community health management as well as organising
and implementing programs, projects and community health events in Ho Chi Minh City.
Marty Dillon, CEO said: “The signing of this MOU further reinforces our TruScreen non-
invasive and real time screening as a technology particularly suited for use in low-and-
middle income countries. We are increasingly recognised by key government agencies of
the ability for TruScreen to be rolled out quickly and economically in large population-based
screening programs.”

This announcement was approved for release by the Board.
-ENDS-

For more information, visit www.truscreen.com or contact:
Marty Dillion
Chief Executive Officer
martindillon@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has
developed and manufactures an AI-enabled device for detecting abnormalities in the
cervical tissue in real-time via measurements of the low level of optical and electrical
stimuli.
TruScreen’s cervical screening technology enables cervical screening, negating sampling
and processing of biological tissues, failed samples, missed follow-up, discomfort, and
the need for costly, specialised personnel and supporting laboratory infrastructure.
The TruScreen device, TruScreen Ultra
®
, is registered as a primary screening device for
cervical cancer screening.
The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical
use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi
Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health
approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has
distributors in 23 countries. In 2021, TruScreen established a manufacturing facility in
China for devices marketed and sold in China, with the “Made in China” registration.
TruScreen technology has been recognised in CSCCP’s (Chinese Society for Colposcopy
and Cervical Pathology) China Cervical Cancer Screening Management Guideline.
TruScreen has been recognised in a China Blue Paper “Cervical Cancer Three Stage
Standardized Prevent and Treatment” published on 28 April 2023, by COGA (Chinese
Obstetricians and Gynaecologists Association).
In financial year 2023 alone, over 140000
1
examinations have been performed
with TruScreen device. To date, over 200 devices have been installed and used in China,
Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen’s vision is “A world
without the cervical cancer”
©
.
To learn more, please visit: www.truscreen.com/.
1
Based on Single Use Sensor sales.

Glossary:
Pap smear (the Papanicolaou smear) test involves gathering a sample of cells from the
cervix, with a special brush. The sample is placed on a glass slide or in a bottle containing
a solution to preserve the cells. Then it is sent to a laboratory for a pathologist to examine
under a microscope. https://www.cancer.net/navigating-cancer-care/diagnosing-
cancer/tests-and-procedures/pap-test
LBC (the liquid-based cytology) test, transfers a thin layer of cells, collected with a brush
from the cervix, onto a slide after removing blood or mucus from the sample. The sample
is preserved so other tests can be done at the same time, such as the human
papillomavirus (HPV) test https://www.cancer.net/cancer-types/cervical-
cancer/diagnosis

HPV (human papilloma virus) test is done on a sample of cells removed from the
cervix, the same sample used for the Pap test or LBC. This sample is tested for the
strains of HPV most commonly linked to cervical cancer. HPV testing may be done by
itself or combined with a Pap test and/or LBC. This test may also be done on a sample
of cells which a person can collect on their own.
https://www.cancer.net/cancer-
types/cervical-cancer/screening-and-prevention

Sensitivity and specificity mathematically describe the accuracy of a test which
reports the presence or absence of a condition. If individuals who have the condition are
considered "positive" and those who don't are considered "negative", then sensitivity is
a measure of how well a test can identify true positives and specificity is a measure of
how well a test can identify true negatives:
• Sensitivity (true positive rate) is the probability of a positive test
result, conditioned on the individual truly being positive.
• Specificity (true negative rate) is the probability of a negative test result,
conditioned on the individual truly being negative (Sensitivity and specificity –
Wikipedia).
For more information about the cervical cancer and cervical cancer screening in New
Zealand and Australia, please see useful links:
New Zealand:
National Cervical Screening Programme | National Screening Unit
(nsu.govt.nz)
Australia: Cervical cancer | Causes, Symptoms & Treatments | Cancer Council